– USA, MA – Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company today announced the appointment of Prathyusha Duraibabu to its Board as an independent director, effective November 19, 2021.
“Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positions at global biotechnology and life sciences companies. I’m very pleased to welcome her to our Board and look forward to her strategic insight and guidance as a member of the Audit Committee,” said CEO, Gary Gillheeney.
Prathyusha Duraibabu will also join the Audit Committee.
About Prathyusha Duraibabu
Ms. Duraibabu currently serves as the CFO of Sangamo Therapeutics (NASDAQ: SGMO), a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Before joining Sangamo, Ms. Duraibabu was Corporate Controller at Pacific Biosciences of California, Inc. (NASDAQ: PACB) from 2010 to 2019, a leading commercial DNA sequencing instrument company. Ms. Duraibabu began her career as an international tax and audit professional and served in a variety of accounting and finance roles of increasing responsibility for companies in the software and semiconductor sectors.
She holds a Bachelor of Accounting from Oxford Brookes University, and an MBA from San Jose State University. She is a Certified Public Accountant.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
For more information: https://organogenesis.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
